Pomegra
Novo Nordisk Stock Jumps 5% After Earnings Beat, Guidance Raise
Why is Novo Nordisk stock up today?
Novo Nordisk (NVO) stock rose about 5% to roughly $42 on Wednesday after the drugmaker beat earnings and raised its 2026 outlook on strong Wegovy pill sales.
Key numbers
| Wegovy pill sales (Q3) | DKK 5.39B+53% vs Q2; forecast DKK 4.62B |
|---|---|
| Adjusted sales (Q3) | DKK 79.2B+4% at constant exchange rates |
| Adjusted operating profit (Q3) | DKK 31.7B+27% at constant exchange rates |
| 2026 sales growth outlook | -2% to +2%from -6% to 0% |
| 2026 free cash flow outlook | DKK 60–70Bfrom DKK 45–55B |
| Peak share gain (intraday) | +6.6%Copenhagen later +3.4% (per [2]) |
What happened
Novo Nordisk (NVO) stock rose about 5% to roughly $42 on Wednesday after the drugmaker beat earnings and raised its 2026 outlook on strong Wegovy pill sales. The weight-loss pill sold 5.4 billion Danish kroner (about $810 million) last quarter, up 53% from the quarter before and above the 4.6 billion analysts expected. Total sales were 79.2 billion kroner, up 4% after removing currency swings. Novo now expects 2026 sales and operating profit to change by between -2% and +2%, up from -6% to flat.
Why it matters
Novo Nordisk makes Wegovy and Ozempic, popular weight-loss and diabetes medicines known as GLP-1 drugs, and this is the third time this year it has raised its own forecast (guidance). That suggests its slide against rival Eli Lilly may be slowing, though Novo shares are still down about 13% this year. Prices for these drugs are also falling, which limits how much sales growth turns into profit.
Who this affects
- MarketbullishMedium impact
- Pharma investors cheer; moves differed by listing and time.
- CompanybullishHigh impact
- Shareholders gain from higher forecast and stronger Wegovy pill demand.
- CompetitorsmixedMedium impact
- Eli Lilly still leads injections, but faces tougher pill rivalry.
- IndustrymixedMedium impact
- Obesity-drug volumes grow while prices keep falling.
Novo Nordisk vs Eli Lilly
How we got here
Novo launches the Wegovy pill in the US.
Eli Lilly reports Q3 revenue up 39% and raises 2026 revenue guidance to $91–92B.
Novo reports Q3, beats forecasts and raises 2026 outlook for the third time this year.
Novo shares rise as much as 6.6% in early trading, then ease back.
What to watch
- Wegovy pill rollout to 20+ countries, now pulled forward from end-2027.H1 2027
- Whether Novo's roughly 80% share of new US pill prescriptions holds against Lilly's Foundayo.Q4 2026
- US drug price cuts, which trimmed net prices by about 30% in the quarter.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
Datadog Stock Falls 14% on Weak Q4 Guidance Despite Q3 Beat
Datadog (DDOG) shares closed at $188.72 as its top AI customer cut usage and Q4 growth slows to 25-26%.
Dow Jumps 3% After Democrats Sweep the Midterms
The Dow (^DJI) closed at 53,356, its best day since April 2025, as investors bet on a divided Washington.
Arista Networks Stock Rises 5% After Earnings Beat
Arista (ANET) sees 2027 sales near $18.5B as AI networking demand lifts third-quarter revenue 58.5% to $3.66B